Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2010-01-07 Regulatory Filings
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2010
Regulatory Filings
2010-01-07 English
FORM 10-Q - AMENDED
Interim / Quarterly Report Q3 2009
2009-12-16 English
FORM 10-Q
Interim / Quarterly Report Q3 2009
2009-11-16 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 16, 2009, reporting the financial results for the third quarter ended September 30, 2009. It includes a press release as an exhibit announcing these results. The document is relatively short (2221 characters) and primarily serves as a current report announcing quarterly financial results rather than containing detailed financial statements or comprehensive analysis. According to the definitions, an initial announcement of quarterly financial results (key highlights only) corresponds to an Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2009-11-16 English
Major Shareholding Notification 2009
Major Shareholding Notification
2009-11-06 English
FORM 8-K FOR OLIVE WAY LEASE TERMINATION
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the termination of a material definitive agreement, namely the Olive Way Building Lease. It does not contain financial statements or detailed financial analysis, nor is it an annual or quarterly report. It is not a proxy, earnings release, or management discussion. The document is short (2640 characters) and serves as a regulatory announcement of a material event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2009-11-05 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.